31 results about "Cardiac index" patented technology

A method for determining and responding in real-time to an increased risk of death relating to a patient with epilepsy is provided. The method includes receiving cardiac data and determining a cardiac index based upon the cardiac data. The method includes determining an increased risk of death associated with epilepsy if the indices are extreme, issuing a warning of the increased risk of death and logging information related to the increased risk of death. Also presented is a second method for determining and responding in real-time to an increased risk of death relating to a patient with epilepsy comprising receiving at least one of arousal data, responsiveness data or awareness data and determining an arousal index, a responsiveness index or an awareness index, where the indices are based on arousal data, responsiveness data or awareness data respectively. The second method includes determining an increased risk of death related to epilepsy if indices are extreme values, issuing a warning of the increased risk of death and logging information related to the increased risk of death. A computer readable program storage device is also provided. Also provided is a method for receiving body data, determining a cardiac, an arousal, a responsiveness, or a kinetic index, determining an increased or increasing risk of death over a first time window relating to a patient with epilepsy and issuing a warning and logging relevant information.

A system for evaluating the cardiovascular system parameters using indicator dilution and non-invasive or minimally invasive detection methods is disclosed. Intravascular indicators are stimulated, and emission patterns detected for computation of cardiac output, cardiac index, blood volume and other indicators of cardiovascular health.

A system and method of non-invasive or minimally invasive evaluating the cardiovascular system parameters to estimate the cardiac output and circulating blood volume of a patient undergoing hemodialysis. Intravascular indicators are stimulated, and emissions patterns detected for computation of cardiac output, cardiac index, blood volume and other indicators of cardiovascular health before and during hemodialysis.

A method includes receiving cardiac data and determining a cardiac index based upon the cardiac data; determining an increased risk of death associated with epilepsy if the indices are extreme, issuing a warning of the increased risk of death and logging information related to the increased risk of death. A second method comprises receiving at least one of arousal data, responsiveness data or awareness data and determining an arousal index, a responsiveness index or an awareness index, where the indices are based on arousal data, responsiveness data or awareness data respectively; determining an increased risk of death related to epilepsy if indices are extreme values, issuing a warning of the increased risk of death and logging information related to the increased risk of death. A non-transitory computer readable program storage device encoded with instructions that, when executed by a computer, perform a method is also provided.

A method and system are presented for use in assessment of at least one cardiac parameter of an individual. An electrodes arrangement is applied to an individual's body, for applying an electrical field to the body and providing an electrical output indicative of a systolic impedance change and of a velocity of said change during a cardiac cycle. Also provided is additional data indicative of at least of the following conditions of the individual: a value of total peripheral resistance (TPR), a value of cardiac index (CI), and existence of the AHF condition. Data corresponding to these condition is analyzed to determine whether the TPR satisfies a first predetermined condition and/or the CI satisfies a predetermined second condition and/or whether the acute heart failure (AHF) condition is identified, to thereby use the data indicative of the measured electrical output and selectively calculate said at least one cardiac parameter based on either the systolic impedance change data or on said data of the velocity of the impedance change.

A system for evaluating the cardiovascular system parameters using indicator dilution and non-invasive or minimally invasive detection and calibration methods are disclosed. Intravascular indicators are stimulated, and emissions patterns detected for computation of cardiac output, cardiac index, blood volume and other indicators of cardiovascular health.

The invention discloses a Chinese herbal medicine compound preparation for treating congestive heart failure and a preparation method thereof. The Chinese herbal medicine compound preparation comprises various components according to the parts by weight: 10-30 parts of ginseng, 10-30 parts of the root of red-rooted salvia, 10-30 parts of safflower, 10-30 parts of rhizoma cyperi, 10-30 parts of bighead atractylodes rhizome, 10-30 parts of angelica, 10-30 parts of peach kernel, 10-30 parts of red paeonia, 10-30 parts of schisandra chinensis, 10-30 parts of pseudo-ginseng, 10-30 parts of cinnamon, 10-15 parts of monkshood, 10-30 parts of ophiopogon root, 10-30 parts of milk weteh, 10-30 parts of asarum, 10-30 parts of notopterygium root, 10-30 parts of spatholobus stem, 10-30 parts of rhizoma atractylodis, 10-15 parts of toad coat, 10-30 parts of folium ginkgo, and 10-30 parts of the rhizome of chuanxiong. The Chinese herbal medicine compound preparation can inhibit platelet aggregation and thrombosis, improves microcirculation, increases coronary blood flow, has the function of cardiac stimulant, can increase cardiac and cardiac index, has the efficacy of dilating blood vessels and depressurization, and can be effectively used for treating patients with clinical congestive heart failure.

A system for evaluating the cardiovascular system parameters using indicator dilution and non-invasive or minimally invasive detection and calibration methods are disclosed. Intravascular indicators are stimulated, and emissions patterns detected for computation of cardiac output, cardiac index, blood volume and other indicators of cardiovascular health.

A system for evaluating the cardiovascular system parameters using indicator dilution and non-invasive or minimally invasive detection and calibration methods are disclosed. Intravascular indicators are stimulated, and emissions patterns detected for computation of cardiac output, cardiac index, blood volume and other indicators of cardiovascular health.

The invention discloses a medicinal composition for treating angina pectoris of coronary heart disease. The medicinal composition consists of the following raw material medicines: cassia twig, officinal magnolia bark, humifuse euphorbia herb, Mongolian dandelion herb, cape jasmine fruit, szechuan lovage rhizome, diverse wormwood herb, processed pinellia tuber, bitter orange, rhizome of swordlike atractylodes, root of lobed kudzuvine, myrrh, arisaema consanguineum schott, cassia seed, costustoot, thinleaf milkwort root-bark, motherwort herb, silktree albizzia bark, safflower, long pepper, szechwan chinaberry fruit, fortune eupatorium herb, panax notoginseng, bezoar, snakegourd fruit, nutgrass galingale rhizome, Chinese thorowax root, mulberry fruit, lychee seeds, lucid ganoderma, dragon's blood, grassleaf sweelflag rhizome, licorice root and cyrtomium rhizome. By adopting the medicinal composition disclosed by the invention, the attack times of angina pectoris of coronary heart disease can be effectively reduced, the attack duration of angina pectoris can be shortened, the occurrence of myocardial infarction can be avoided, sudden death caused by angina pectoris can be avoided, and adverse reactions cannot be caused; and the medicinal composition is accurate in curative effect and small in toxic or side effect, ensures that the cardiac stroke volume and cardiac output can be increased, cardiac indexes can be increased, the cardiac pumping functions can be enhanced, the ventricular diastolic functions and arterial compliance can be improved, coronary arteries can be expanded and the blood flow volume of the coronary arteries can be increased, and has significant curative effects on the aspect of treating angina pectoris of coronary heart disease.

Mean Pulmonary Arterial Pressure (MPAP), Mean Pulmonary Capillary Wedge Pressure (MPCWP) and Cardiac Index are all determinable (in a method or employing apparatus) from Central Venous Pressure (CVP), Mean Arterial Pressure (MAP), Heart Rate (HR), and Core Body Temperature (T) from the following relationships: MPAP=(a×MAP)+CVP (for MAP<58), or Va; MPAP=(a×MPAP)+CVP−(10×INT[(MAX {MAP−109), (CVP−7),0})/10]) for MAP>58); Vb; MPCWP=(b×MPAP)+CVP−(10×INT [CVP−7/10]; and VI; CI=K (T.CVP)/HR2, VII; where a and b are about 0.15; MAX (x, y, z)=largest of the three terms x, y, and z; INT [x]=integer part of x; MAP and CVP is measured in mmHg; T in Celsius and HR in counts per minute; CI is liters per square meter per minute; and K is a variable constant whose value is between 0 and 1000 depending on the values of CVP and HR.

The invention discloses a cardiac function assessment method for accurate selection of athletes. The method includes the following steps: 1) testing a per stroke volume SV1 and a heart rate HR1 of a tested athlete at rest, and calculating cardiac output per minute CO1 at rest according to CO being SV*HR; 2) performing a quantitative load cardiovascular exercise test on the athlete, and measuring an average anaerobic power PP; 3) immediately testing the athlete after completing the exercise in step 2), measuring a per stroke volume SV2 and a heart rate HR2 immediately after exercise, and calculating the calculating cardiac output per minute CO2 immediately after exercise; 4) calculating a cardiac index CI1 at rest and a post-exercise immediate cardiac index CI2 according to the cardiac index CI being cardiac output per minute CO/body surface area BSA; and 5) calculating a cardiac reserve index CRI: CRI being K*PP/(CI2-CI1), wherein the CRI value is positively correlated with the cardiacreserve capacity, and accordingly, making a more accurate quantitative assessment of the cardiac function level of the tested athletes.

The invention relates to application of a qi-tonifying dripping pill containing radix astragali and root of red-rooted salvia to preparation of a medicament for improving myocardial fibrosis and myocardial hypertrophy. The qi-tonifying dripping pill containing radix astragali and root of red-rooted salvia is refined from active ingredients in radix astragali, root of red-rooted salvia, pseudo-ginseng and dalbergia heartwood extracted by modern technology. The invention aims to provide application of qi-tonifying dripping pill containing radix astragali and root of red-rooted salvia to preparation of the medicament for improving myocardial fibrosis and inhibiting further myocardial hypertrophy. According to the application in the invention, after generation of ventriculus sinister hypertrophy, the qi-tonifying dripping pill containing radix astragali and root of red-rooted salvia can improve myocardial fibrosis, substantially inhibit increase of wall thickness cardiac index and body mass index in ventriculus sinister diastasis, increase ejection fraction and shortening fraction of the ventriculus sinister and reduce scope of myocardial fibrosis.

The invention discloses a medicine composition with active components of carvedilol and a medicinal salt thereof, and fimasartan. The invention also relates to an application of the medicine composition in treating hypertension and complications thereof, and an application of the medicine composition in treating congestive cardiac failure. In the medicine composition, a weight ratio of carvedilol and medicinal salt thereof to fimasartan is 1:0.01-1000. The components of the medicine composition are clear. When the medicine composition is used for treating hypertension and complications thereof, a substantial synergetic effect of the two medicine components is shown, and stable reduction of blood pressure can be realized; when the medicine composition is used for treating congestive cardiac failure, various cardiac indexes are substantially enhanced, a treatment effect is substantial, and a substantial synergetic effect of the two medicine components is shown.

This invention relates to a gene therapy method for inducing pulmonary vasodilation. More specifically, this invention involves introducing the nitric oxide synthase gene into lungs resulting in pulmonary vasodilation. This results in a hypotensive effect in the pulmonary circulation which does not significantly affect systemic blood pressure or cardiac index. This method is useful to treat primary pulmonary hypertension or pulmonary hypertension secondary to various disease states.